Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status in ovarian cancer

Purpose: Ovarian cancer is the most deadly of all gynecologic malignancies, due in part to the diagnosis at an advanced stage caused by the deficiency of specific marks and symptoms, by the absence of reliable tests for screening, and by early detection. Materials and Methods: Insulin-like growth factor-I (IGF-I) is known to be involved in the development and promotion of diverse examples of solid tumors including ovarian cancer. IGF-I levels in local tissue are subject to both endocrine and paracrine/autocrine regulation. Results: Most patients will react initially to treatment, but almost 70% of them will have a recurrence. Consequently, new therapeutic modalities are urgently required to overcome chemoresistance observed in ovarian cancer patients. IGF-1R expression was evaluated immunohistochemically in tissue microarray blocks constructed from 1,200 ovarian cancer samples collected from three medical institutions. Conclusion: Evidence accumulates suggesting that the insulin/insulin growth factor (IGF) pathways could play a good therapeutic target in various cancers, including ovarian cancer.

Insulin-like growth factor-1 receptor (IGF1-R); Ovarian cancer; Immunostaining.

[1] Heinzelmann-Schwarz V.A., Gardiner-Garden M., Henshall S.M., Scurry J.P., Scolyer R.A., Smith A.N., et al.: “A distinct molecular profile associated with mucinous epithelial ovarian cancer”. Br J. Cancer, 2006, 94, 904.

[2] Sherman M.E., Mink P.J., Curtis R., Cote T.R., Brooks S., Hartge P., et al.: “Survival among women with borderline ovarian tumors and ovarian carcinoma”. Cancer, 2004, 100, 1045.

[3] Cullen K.J., Yee D., Sly W.S., Perdue J., Hampton B., Lippman M.E., et al.: ‘Insulin-like growth factor receptor expression and function in human breast cancer”. Cancer Res 1990, 50, 48.

[4] Baserga R., Peruzzi F., Reiss K.: “The IGF-1 receptor in cancer biology”. Int. J. Cancer, 2003, 107, 873.

[5] Shimizu C., Hasegawa T., Tani Y., Takahashi F., Takeuchi M., Watanabe T., et al.: “Expression of insulin-like growth factor 1 receptor in primary breast cancer: Immunohistochemical analysis”. Human Pathol., 2004, 35, 1537.

[6] Tao Y., Pinzi V., Bourhis J., Deutsch E.: “Mechanisms of Disease: signaling of the insulin-like growth factor 1 receptor pathway [mdash] therapeutic perspectives in cancer”. Nat. Clin. Prac. Oncol., 2007, 4, 591.

[7] Sell C., Dumenil G., Deveaud C., Miura M., Coppola D., DeAngelis T., et al.: “Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts”. Molecul. cellular biol., 1994; 14, 3604.

[8] Sell C., Rubini M., Rubin R., Liu J.P., Efstratiadis A., Baserga R.: “Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor”. Proceed Nat. Acad. Sci., 1993, 90, 11217.

[9] Long L., Rubin R., Baserga R., Brodt P.: “Loss of the metastatic phe-notype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor”. Cancer Res., 1995, 55, 1006.

[10] Zeigler M.E., Krause S., Karmiol S., Varani J.: “Growth factor-induced epidermal invasion of the dermis in human skin organ culture: dermal invasion correlated with epithelial cell motility”. Invasion Metast., 1995, 16, 3.

[11] Lee H.: “Measuring cognitive load with electroencephalography and self-report: focus on the effect of English-medium learning for Korean students”. Edu. Psychol., 2013, 1, 2183.

[12] Werner H.: “For debate: the pathophysiological significance of IGF-I receptor overexpression: new insights”. Pediatr. Endocrinol. Rev., 2009, 7, 2.

[13] Kaku T., Ogawa S., Kawano Y., Ohishi Y., Kobayashi H., Hirakawa T., et al.: “Histological classification of ovarian cancer”. Med. Electron. Microsc., 2003, 36, 9.

[14] Bookman M.A.: “Standard treatment in advanced ovarian cancer in 2005: the state of the art”. Int. J. Gynecol. Cancer, 2005, 15, 212.

[15] Scully R.E., Young R.H., Clement P.B.: “General aspects and classification. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament”. In: Scully RE, (ed). Atlas of tumor pathology, third series. Washington DC: Armed forces institute of pathology; 1998, 30.

[16] Berek, Jonathan S.: “Epithelial ovarian cancer’. Pract. Gynecol. Oncol. 2000, 3, 457.

[17] Nielsen T.O., Andrews H.N., Cheang M., Kucab J.E., Hsu F.D., Ragaz J., et al.: “Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17- allylamino geldanamycin”. Cancer. Res., 2004; 64, 286.

[18] McGuire W.P., Blessing J.A., Bookman M.A., Lentz S.S., Dunton C.J.: “Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study”. J. Clin. Oncol., 2000, 18, 1062.

[19] ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I., et al.: “Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer”. J. Clin. Oncol., 1997, 15, 2183.

[20] Bae Y.K., Gong G., Kang J., Lee A., Cho E.Y., Lee J.S., Suh K.S., Lee D.W., Jung W.H.: “HER2 Status by Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast Cancer”. J. Breast. Cancer, 2012, 15, 381.

[21] Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al.: “American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer”. J. Clin. Oncol., 2007, 25, 118.

[22] De Cecco L., Marchionni L., Gariboldi M., Reid J.F., Lagonigro

M. S., Caramuta S., et al.: “Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2”. Oncogene, 2004, 23, 8171.

[23] Chen V.W., Ruiz B., Killeen J.L., Cote T.R., Wu X.C., Correa C.N.: “Pathology and classification of ovarian tumors”. Cancer, 2003, 97, 2631.

[24] Fleming I.D., Cooper J.S., Henson D.E., Hutter R.V.P., Kennedy B.J., Murphy G.P., et al.: “AJCC Cancer Staging Manual”. Philadelphia: Lippincott-Raven Publishers, 1997, 231.

[25] Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al.: ‘Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study”. J. Clin. Oncol., 2000, 18, 106.

[26] McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E. E., Look K.Y., et al.: “Cyclophosphamide and cisplatin compared with paclitaxel and 327 cisplatin in patients with stage III and stage IV ovarian cancer’. N. Engl. J. Med. 1996, 334, 1.

[27] Chakraborty A.K., Liang K., DiGiovanna M.P.: “Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer”. Cancer Res., 2008, 68, 1538.